Quick Answer
ZyVersa Therapeutics, Inc. reported Net Income of -$24.95 million for fiscal year 2025.
ZyVersa Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$24.95M | -165.1% |
| 2024 | -$9.41M | +90.4% |
| 2023 | -$98.30M | -130932.5% |
| 2022 | -$75.0K | +99.5% |
| 2022 | -$14.05M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$19.81M | -724.8% | -795.6% |
| June 30, 2025 | -$2.21M | +20.0% | +2.0% |
| March 31, 2025 | -$2.26M | +20.2% | +6.0% |
| September 30, 2024 | -$2.40M | +17.3% | +13.1% |
| June 30, 2024 | -$2.76M | +96.5% | +2.2% |
| March 31, 2024 | -$2.83M | +20.2% | +2.6% |
| September 30, 2023 | -$2.90M | -327.4% | +96.3% |
| June 30, 2023 | -$78.51M | -19845.5% | -2115.4% |
- ZyVersa Therapeutics, Inc. showed a decrease of -165.1% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, ZyVersa Therapeutics, Inc.’s net income has declined by 77.6% (from -$14.05 million to -$24.95 million).
- The most recent figure is from ZyVersa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: